Calendario›LQDA›LIQ861 · RE-WARM
LIQ861 · RE-WARM
A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks
Ensayo de Liquidia Corp en Raynaud's Phenomenon Secondary to Systemic Sclerosis (del registro, en inglés).
- Fase
- Fase 2
- Estado
- Aún sin reclutar
- Participantes
- 75
- Fin del objetivo primario
- feb 2027
previstos
estimado por el promotor
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, abierto. Comenzó en oct 2026.
Qué mide
Participant incidence of tolerated dose(s) of LIQ861 defined as a dose level or dose regimen at which ≥80% of participants complete the Treatment Period with ≥80% compliance without permanent discontinuation of LIQ861 due to a TEAE (del registro, en inglés) (21 dias)
Cómo lo describe el promotor
En el documentoEn inglés, del registroSystemic sclerosis (SSc) is a rare autoimmune disease in which many patients experience Raynaud's phenomenon (RP) - painful episodes where commonly fingers or toes change color and become painful, numb, or tingly, usually triggered by cold or stress. This open-label study is testing an inhaled powder form of treprostinil (LIQ861) to find out which doses can be taken safely and comfortably by adults with SSc who have frequent symptomatic RP attacks. About 75 adults will be randomly assigned (2 to 1) to either a dose-titration group or a fixed low-dose group. The study also explores whether treatment reduces the number, severity, and impact of RP attacks. The main goal is to identify tolerated dose(s).
Más ensayos de LQDA
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| L606 inhalation suspension | Fase 3 | En marcha, sin reclutar | mar 2025 (real) |
| LIQ861 Inhaled Treprostinil | Fase 3 | En marcha, sin reclutar | may 2025 (prevista, ya pasada: sin actualizar en el registro) |
| LIQ861 | Fase 4 | Aún sin reclutar | may 2027 (prevista) |
| LIQ861 · ASCENT | no aplica | Reclutando pacientes | jul 2027 (prevista) |
| L606 · Re-Spire | Fase 3 | Reclutando pacientes | jul 2029 (prevista) |
| Inhaled dry powder treprostinil | Fase 2 | Interrumpido | dic 2020 (real) |
Todos los de LQDA, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT07748000), actualizada en ago 2026.